vTv Therapeutics Inc. is a biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. Its lead product candidate cadisegliatin (TTP399) is a liver selective glucokinase activator being evaluated as an oral adjunctive therapy to insulin for type 1 diabetes. The company also advances a pipeline of small molecule programs including a GLP 1 receptor agonist a RAGE antagonist a PPAR delta agonist an Nrf2 Bach1 modulator and a PDE4 inhibitor. These programs target diabetes obesity inflammatory disorders and related conditions. vTv Therapeutics Inc. seeks to improve patient outcomes by addressing unmet needs in glycemic control and hypoglycemia risk. The cadisegliatin program is currently in a Phase 3 trial known as CATT1 evaluating its effect on hypoglycemia outcomes in type 1 diabetes patients. Additional supportive studies include a thorough QT trial and a Phase 2 trial using hybrid closed loop insulin infusion systems. The company also progressed a Phase 2 trial of cadisegliatin in type 2 diabetes in partnership with G42 Investments in the Middle East region.

vTv Therapeutics Inc. generates revenue primarily through collaboration agreements licensing arrangements and milestone payments. The company has received upfront cash payments and potential future milestones from partners such as Newsoara BioPharma Co. Ltd. for its PDE4 inhibitor program and G42 Investments AI Holding RSC Ltd. for development of cadisegliatin in the Middle East and Africa. Additional revenue stems from licensing deals with Cantex Pharmaceuticals Inc. for azeliragon and Novo Nordisk A/S for glucokinase activator technology. The company also raises capital through private placements of its equity securities to support research and development activities. In May 2025 the company closed a private placement of Class A common stock and pre funded warrants generating approximately $80 million in gross proceeds before expenses. The amendment to the license agreement with Newsoara BioPharma Co. Ltd. delivered a $20 million upfront payment and eligibility for up to $115 million in milestone payments. Royalties from the Newsoara agreement are structured in the mid single digits on net sales.

vTv Therapeutics Inc. competes in the biopharmaceutical sector with a focus on diabetes and inflammatory disease therapies. Its liver selective glucokinase activator cadisegliatin offers a novel mechanism that may reduce hypoglycemia without increasing ketosis risk differentiating it from existing oral anti diabetic agents. The company holds Breakthrough Therapy designation from the FDA for cadisegliatin in type 1 diabetes which can accelerate development and review. Partnerships with entities such as G42 Investments and Newsoara provide funding and commercialization reach in key geographic markets. Intellectual property protection across multiple drug candidates and a diversified pipeline further strengthen its competitive stance against larger pharmaceutical firms and specialized biotech rivals. The company’s patent portfolio includes multiple families covering crystal forms formulations and methods of use for cadisegliatin with expected expiration dates extending into the 2030s. This intellectual property base supports exclusivity and potential licensing revenue. Additionally vTv Therapeutics Inc. benefits from a lean organizational structure that enables rapid decision making and focused allocation of resources to its lead program.

The company serves patients with type 1 and type 2 diabetes who require adjunctive therapies to improve glycemic control and reduce hypoglycemia episodes. Its collaboration partners include G42 Investments AI Holding RSC Ltd. Newsoara BioPharma Co. Ltd. Cantex Pharmaceuticals Inc. and Novo Nordisk A/S. These partners provide clinical development support regulatory expertise and potential commercialization channels for vTv Therapeutics Inc. pipeline assets. Beyond patients the company’s therapies are intended to support healthcare providers and payers seeking effective tools to manage diabetes related complications. Collaborations with academic institutions and contract research organizations also contribute to preclinical and clinical development efforts.